| Regulatory function of a malleable protein matrix as a novel fermented whey product on features defining the metabolic syndrome. | |
| | |
MedLine Citation:
|
PMID: 20406141 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Previously, we reported that a malleable protein matrix (MPM), composed of whey fermented by a proprietary Lactobacillus kefiranofaciens strain, has immunomodulatory and anti-inflammatory properties. MPM consumption leads to a considerable reduction in the cytokine and chemokine production (tumor necrosis factor-alpha, interleukin-1beta, and interleukin-6), thus lowering chronic inflammation or metaflammation. Inhibition of metaflammation should provide positive impact, particularly in the context of dyslipidemia, insulin resistance, and hypertension. In this study, we investigated whether short-term MPM supplementation ameliorates those features of metabolic syndrome (MetS). The ability of MPM to potentially regulate triglyceride level, cholesterol level, blood glucose level, and hypertension was evaluated in different animal models. MPM lowers triglyceride level by 37% (P < .05) in a poloxamer 407 dyslipidemia-induced rat model. It also reduces total cholesterol by 18% (P < .05) and low-density lipoprotein-cholesterol level by 32% (P < .05) and raises high-density lipoprotein-cholesterol level by 17% (P < .01) in Syrian Golden hamsters fed a high fat/high cholesterol diet for 2 weeks. MPM reestablishes the fasting glucose insulin ratio index to normal levels (P = .07) in this latter model and lowers the plasma glucose level area under the curve (-10%, P = .09) in fructose-fed rats after 2 weeks of treatment. In spontaneously hypertensive rats, MPM-treated animals showed a reduction of SBP by at least 13% (P < .05) for 4 weeks. Results from this study suggest that MPM is a functional ingredient with beneficial effects on lipid metabolism, blood glucose control, and hypertension that might contribute to the management of MetS and thus reducing the risk of cardiovascular diseases. |
| | |
Authors:
|
J Beaulieu; E Millette; E Trottier; L-P Précourt; C Dupont; P Lemieux |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Journal of medicinal food Volume: 13 ISSN: 1557-7600 ISO Abbreviation: J Med Food Publication Date: 2010 Jun |
Date Detail:
|
Created Date: 2010-06-04 Completed Date: 2010-08-27 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9812512 Medline TA: J Med Food Country: United States |
Other Details:
|
Languages: eng Pagination: 509-19 Citation Subset: IM |
Affiliation:
|
Technologie Biolactis Inc., Laval, Québec, Canada. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Blood Glucose / drug effects Cholesterol / blood Cricetinae Disease Models, Animal Female Fermentation* Humans Hypoglycemic Agents / administration & dosage, analysis Lactobacillus / metabolism* Male Mesocricetus Metabolic Syndrome X / blood, drug therapy* Milk Proteins / administration & dosage*, analysis Random Allocation Rats Rats, Inbred SHR |
| Chemical | |
Reg. No./Substance:
|
0/Blood Glucose; 0/Hypoglycemic Agents; 0/Milk Proteins; 0/whey protein; 57-88-5/Cholesterol |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Isoflavone Composition, Total Polyphenolic Content, and Antioxidant Activity in Soybeans of Differen...
Next Document: Physiologically based pharmacokinetics of molecular imaging nanoparticles for mRNA detection determi...